Stay updated with breaking news from Label Extension Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
John W. Day, MD, PhD, Professor of Neurology and Pediatrics, and Director, Division of Neuromuscular Medicine, Stanford University School of Medicine and a principal investigator in END-DM1,...
– Totality of data from these ongoing studies suggest clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification –– Phase 1/2a ADMIRAL Study Data STK-001 (70mg): Patients treated with 2 or 3 ini...
Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studiesSustained reduction in frequency of drop...
Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studiesSustained reduction in frequency of drop seizures among Lennox-Gastaut patients and... | June 18, 2023